CymaBay Therapeutics, Inc. (CBAY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Newark, CA, United States. The current CEO is Sujal A. Shah.
CBAY has IPO date of 2014-02-03, 101 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.73B.
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and chronic metabolic diseases. The company's lead program, seladelpar (MBX-8025), a selective peroxisome proliferator-activated receptor delta agonist, is currently in Phase III clinical trials for primary biliary cholangitis (PBC) and has completed Phase 2b studies for nonalcoholic steatohepatitis (NASH). CymaBay is also advancing MBX-2982 in Phase 2a development for hypoglycemia management in type 1 diabetics. The company operates under licensing agreements with ABW Cyclops SPV LP for PBC development and maintains a worldwide license from Janssen Pharmaceuticals for research and commercialization of compounds targeting metabolic disease targets. Founded in 1988 as Metabolex, Inc. and headquartered in Newark, California, CymaBay is dedicated to addressing significant unmet medical needs in hepatic and metabolic disease treatment.
